Raymond James Financial’s Cytokinetics CYTK Stock Holding History

Raymond James Financial’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.52M	Sell	68,503 -13,892	-17%	-$883K	﹤0.01%	2679
2025 Q4	$5.24M	Buy	82,395 +40,187	+95%	+$2.5M	﹤0.01%	2479
2025 Q3	$2.32M	Buy	42,208 +36,759	+675%	+$1.51M	﹤0.01%	3065
2025 Q2	$180K	Sell	5,449 -3,066	-36%	-$107K	﹤0.01%	4566
2025 Q1	$342K	Buy	8,515 +3,115	+58%	+$143K	﹤0.01%	4139
2024 Q4	$254K	Buy	+5,400	New	+$280K	﹤0.01%	4279

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Raymond James Financial's CYTK Position: Q1 2026 in Review

Raymond James Financial reduced its Cytokinetics (CYTK) stake by 17% in Q1 2026, selling an estimated $883K and leaving 68,503 shares worth $4.52M. The position accounts for ﹤0.01% of the portfolio, ranked #2679.

Raymond James Financial first reported a position in CYTK in Q4 2024 and has held it in 6 quarters since. The position peaked at $5.24M in Q4 2025. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

Raymond James Financial held 68,503 shares of Cytokinetics worth $4.52M as of Q1 2026.
Raymond James Financial sold 13,892 Cytokinetics shares in Q1 2026, an estimated $883K.
Cytokinetics made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #2679 holding.
Raymond James Financial first reported a position in Cytokinetics in Q4 2024 and has held it in 6 quarters since.
Raymond James Financial's Cytokinetics position peaked at $5.24M in Q4 2025.
439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.